Advanced search
Publication Cover
Journal of Dermatological Treatment Volume 34, 2023 - Issue 1
Submit an article Journal homepage
1,089
Views
0
CrossRef citations to date
0
Altmetric
Letter to the Editor

Safety of anti-IL-23 drugs in patients with moderate-to-severe plaque psoriasis and previous tuberculosis infection: a monocentric retrospective study

Luciano Ibbaa Dermatology Unit, IRCCS Humanitas Research Hospital, Rozzano, Italy;b Department of Biomedical Sciences, Humanitas University, Milan, ItalyCorrespondence[email protected]
View further author information
,
Luigi Gargiuloa Dermatology Unit, IRCCS Humanitas Research Hospital, Rozzano, Italy;b Department of Biomedical Sciences, Humanitas University, Milan, ItalyView further author information
,
Carlo Alberto Vignolia Dermatology Unit, IRCCS Humanitas Research Hospital, Rozzano, Italy;b Department of Biomedical Sciences, Humanitas University, Milan, ItalyView further author information
,
Giovanni Fiorilloa Dermatology Unit, IRCCS Humanitas Research Hospital, Rozzano, Italy;b Department of Biomedical Sciences, Humanitas University, Milan, ItalyView further author information
,
Mario Valentia Dermatology Unit, IRCCS Humanitas Research Hospital, Rozzano, Italy;b Department of Biomedical Sciences, Humanitas University, Milan, ItalyView further author information
,
Antonio Costanzoa Dermatology Unit, IRCCS Humanitas Research Hospital, Rozzano, Italy;b Department of Biomedical Sciences, Humanitas University, Milan, ItalyView further author information
&
Alessandra Narcisia Dermatology Unit, IRCCS Humanitas Research Hospital, Rozzano, ItalyView further author information
 show all
Article: 2241585 | Received 20 Jun 2023, Accepted 21 Jul 2023, Published online: 28 Jul 2023

References

  • Griffiths CEM, Armstrong AW, Gudjonsson JE, et al. Psoriasis. Lancet. 2021;397(10281):1–3. doi:10.1016/S0140-6736(20)32549-6.
  • Gargiulo L, Ibba L, Malagoli P, et al. Real-life effectiveness and safety of guselkumab in patients with psoriasis who have an inadequate response to ustekinumab: a 104-week multicenter retrospective study - IL PSO (ITALIAN LANDSCAPE PSORIASIS). J Eur Acad Dermatol Venereol. 2023;37(5):1017–1027. doi:10.1111/jdv.18913.
  • Narcisi A, Valenti M, Gargiulo L, et al. Real-life effectiveness of tildrakizumab in chronic plaque psoriasis: a 52-week multicentre retrospective study-IL PSO (Italian landscape psoriasis). J Eur Acad Dermatol Venereol. 2023;37(1):93–103. doi:10.1111/jdv.18594.
  • Souto A, Maneiro JR, Salgado E, et al. Risk of tuberculosis in patients with chronic immune-mediated inflammatory diseases treated with biologics and tofacitinib: a systematic review and meta-analysis of randomized controlled trials and long-term extension studies. Rheumatology (Oxford). 2014;53(10):1872–1885. doi:10.1093/rheumatology/keu172.
  • Fowler E, Ghamrawi RI, Ghiam N, et al. Risk of tuberculosis reactivation during interleukin-17 inhibitor therapy for psoriasis: a systematic review. J Eur Acad Dermatol Venereol. 2020;34(7):1449–1456. doi:10.1111/jdv.16254.
  • Gargiulo L, Pavia G, Valenti M, et al. Safety of biologic therapies in patients with moderate-to-Severe plaque psoriasis and concomitant viral hepatitis: a monocentric retrospective study. Dermatol Ther (Heidelb). 2022;12(5):1263–1270. doi:10.1007/s13555-022-00726-w.
  • Mourik BC, Lubberts E, de Steenwinkel JEM, et al. Interactions between type 1 interferons and the Th17 response in tuberculosis: lessons learned from autoimmune diseases. Front Immunol. 2017;8:294. Published 2017 Apr5. doi:10.3389/fimmu.2017.00294.
  • Mastorino L, Dapavo P, Trunfio M, et al. Risk of reactivation of latent tuberculosis in psoriasis patients on biologic therapies: a retrospective cohort from a tertiary care Centre in Northern Italy. Acta Derm Venereol. 2022;102:adv00821. Published 2022 Nov 29. doi:10.2340/actadv.v102.1982.
  • Nogueira M, Warren RB, Torres T. Risk of tuberculosis reactivation with interleukin (IL)-17 and IL-23 inhibitors in psoriasis - time for a paradigm change. J Eur Acad Dermatol Venereol. 2021;35(4):824–834. doi:10.1111/jdv.16866.
  • Puig L, Tsai TF, Bhutani T, et al. Safety in moderate-to-severe plaque psoriasis patients with latent tuberculosis treated with guselkumab and anti-tuberculosis treatments concomitantly: results from pooled phase 3 VOYAGE 1 & VOYAGE 2 trials. J Eur Acad Dermatol Venereol. 2020;34(8):1744–1749. doi:10.1111/jdv.16460.
  • Gordon KB, Lebwohl M, Papp KA, et al. Long-term safety of risankizumab from 17 clinical trials in patients with moderate-to-severe plaque psoriasis. Br J Dermatol. 2022;186(3):466–475. doi:10.1111/bjd.20818.
  • Blauvelt A, Leonardi CL, Gooderham M, et al. Efficacy and safety of continuous risankizumab therapy vs treatment withdrawal in patients with moderate to severe plaque psoriasis: a phase 3 randomized clinical trial. JAMA Dermatol. 2020;156(6):649–658. doi:10.1001/jamadermatol.2020.0723.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.